Why Doximity Stock Skyrocketed on Friday

Doximity shares surged after management said its AI tools are generating strong unit economics, earning “more than 10x” revenue per AI Search than the cost to run it. In fiscal Q1 (ended June 30), revenue rose 7% YoY to $156.6M, but adjusted EBITDA fell 6% to $74.8M as the company continued heavy AI investment. Usage is accelerating with AI prompt volume up 25% QoQ and AI Scribe note-taking users growing 10x year-over-year, supported by independent study results showing Doximity Ask ranked highest among 24 clinical AI models.

Analysis

DOCS is being re-rated less as a healthcare networking site and more as a distribution layer for clinical workflow AI. If management can keep AI inference costs below the revenue it attaches to search, scribing, and engagement, the operating leverage could be meaningfully better than the market is modeling; that is the real reason the multiple can expand, not the model ranking itself.

The immediate risk is that investors are extrapolating early usage into durable economics before seeing conversion into total revenue growth or margin stability. Over the next 1-3 months, the key catalyst is whether AI adoption shows up in guidance as higher ARPU, lower churn, or expanding gross margin; over 6-18 months, the question is whether large-model vendors and workflow competitors commoditize the feature set and push DOCS back toward a standard digital media valuation.

Second-order winners are limited but real: higher prompt volume and scribe usage create incremental demand for cloud inference, so NVDA gets a tiny tailwind, though not enough to matter near-term. Losers are telehealth and clinical workflow peers that lack proprietary clinician distribution, because AI utility increasingly becomes a retention lever rather than a standalone feature. The contrarian point is that the market may be underestimating distribution advantage and overestimating model IP; if clinicians keep returning because the product saves time, the AI economics can be durable even if the underlying models become generic.

Key Decisions for Investors

• Go tactically long DOCS on any post-gap consolidation, with a 1-3 month horizon; thesis works if next print confirms AI-driven engagement converts into revenue or margin support rather than just higher usage.
• Use a DOCS / TDOC pair trade to express the view that proprietary clinician distribution plus AI monetization will outperform undifferentiated telehealth exposure over the next 3-6 months.
• If options liquidity is adequate, buy a 3-6 month DOCS call spread after the first volatility crush; the setup is asymmetric if management can show AI attach rates are translating into incremental monetization.